All News

FDA logo

FDA Warning on CAR-T Cell Therapy

d Jack Cush, MD

On Nov. 28, 2024, FDA issued a safety alert regarding CAR-T cell immunotherapies; noting reports of T-cell malignancies (CAR-positive lymphoma) arising in patients treated with BCMA- or CD19-directed autologous CAR T cell immunotherapies and that if there is a risk, this only applies to currently approved BCMA-directed and CD19-directed genetically modified autologous CAR T cell immunotherapies. 

Read Article
female with hands

ICYMI: Are Rheumatologists doing Enough for Cervical Cancer?

d Eric Dein, MD

Should rheumatologists be counseling patients on cervical cancer prevention and screening?

Read Article
PSA2L.jpg

ICYMI: How early is early in psoriatic arthritis?

d Antoni Chan, MD, PhD

Guidelines (ACR/EULAR/GRAPPA) for the management of psoriatic arthritis (PsA) recommend the early referral of patients with the suspected condition for early assessment and treatment.

Read Article
obesity.knee_.arthritis.jpg

Slower Weight Loss May Affect Osteoarthritis Survival

d EurekAlert!

Arthritis & Rheumatology has published a new study that suggests knee or hip osteoarthritis patients who are overweight or obese may have less premature death if slow to moderate rate of weight loss results from anti-obesity medications.

Read Article
pregnancy,doctor,consult

ICYMI: How do we manage difficult discussions about pregnancy in RA?

d David Liew, FRACP

Most rheumatologists know that it is important to get pregnancy planning right for women of childbearing age living with rheumatic diseases. That is easier said than done, though: the details are difficult, it is overwhelming for the patient, and the conversations are hard.

Read Article
ICYMI: The Fallacy of Biologic Treatment to Prevent Rheumatoid Arthritis The window of opportunity concept in RA then shifted our focus to trying to treat disease earlier and more aggressively to improve long term outcomes. https://t.co/NTjYbMJJb6 https://t.co/TYuY1Q11xZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Venous Thromboembolic Risk with Joint Replacement Save A recent study suggests that thromboprophylaxis strategies should be tailored to individual risk of thrombosis and bleeding. https://t.co/FKOsNkWMqz https://t.co/XH4SiQ735g

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: New Biomarkers and Therapeutics Show Potential in Still's Disease AOSD is a rare complex, sporadic, systemic autoinflammatory disease similar to sJIA characterized by sustained fever, salmon-colored rash, and arthritis . https://t.co/ZU0XFecPyP https://t.co/GLPsf73Hj0

Links:

Dr. John Cush RheumNow ( View Tweet)
Kuwait #RA registry study - shows in RA, the Uric acid level is inversely proportional to RA disease activity. 1054 RA pts, 15% had high UA level; lower DAS28 score associated w/ higher UA (p=0.032) OR 1.39; but higher HAQ assoc w/ higher UA https://t.co/muN0BFDs2Z https://t.co/VMdCgGPwPB

Links:

Dr. John Cush RheumNow ( View Tweet)
Early bird pricing has been extended! Register today! https://t.co/xvGZgXxRs8 https://t.co/kiXk3TEvnD

Links:

Dr. John Cush RheumNow ( View Tweet)
Palmoplantar pustulosis (PPP) is difficult to treat; w/ few reports of JAKi efficacy. Now a report of 21 PPP pts given bimekizumab and 17 patients showed complete clearance in 1 to 4 months. SAPHO pts had complete clearance of skin & improved joint pain https://t.co/aHEiXZJGD8 https://t.co/QOuf8nsBXW

Links:

Dr. John Cush RheumNow ( View Tweet)
UK Dermatology Registry of 13 699 Psoriasis pts on biologics (25K biologic exposures) found 1% risk of paradoxical eczema. Biologics included inhibitors of TNF, IL-17, IL12/23, IL-23. Lowest risk w/ IL-23i (0.56/100kPY), and higher w/ IL-17i (1.22) https://t.co/SorkOl5G0J https://t.co/msNSJ0l9M4

Links:

Dr. John Cush RheumNow ( View Tweet)
Systematic review (3 studies) RA pts shows bariatric surgery (n=6700) can significantly lower disease activity at 12 mos and reduce comorbidities (OR=0.45) and in-hospital mortality (OR=0.41). BMI at baseline and after BS was 43.1 & 29.7kg/m2, respectively https://t.co/3Uweb5spGC https://t.co/2TAA2ppZpy

Links:

Dr. John Cush RheumNow ( View Tweet)
RCT 114 fibromyalgia pts Rx w/ cognitive behavioral Tx (CBT) vs control education. CBT had significant reduction in pain catastrophizing, pain interference & Sxs w/ improved function; neuroimaging in 98 pts also showed comparable improvement https://t.co/bKwREZdDF0 https://t.co/XkZJAMBfld

Links:

Dr. John Cush RheumNow ( View Tweet)

Polands disease study (sarcoidosis 78.6K; #AOSD 3294; systemic sclerosis 35.5K) betw 2009-2018. Avg hospitalization was 5.39 days sarcoidosis, 6.22 days scleroderma, & 7.44 days for Still’s (latter decr 11.7 to 5.8, betw 2008-2014) https://t.co/OcNzt7IKC5 https://t.co/uPcbOyizQN

Links:

Dr. John Cush RheumNow ( View Tweet)
Naltrexone was NOT superior to placebo in a blinded RCT of 99 Fibromyalgia pts. Pain decreased –1·3 points w/ NAL vs –0·9 in PBO (p=0·27). D/C were similar (8% vs 6%). NAL may improve improve memory problems in FM pts. https://t.co/5i98Jr4u84 https://t.co/SkEbLaMfvI

Links:

Dr. John Cush RheumNow ( View Tweet)
Post-Menopausal Osteoporosis Review and Recommendations A recent New England Journal review of post-menopausal osteoporosis (OP) provided updated information, strategies and a review of guidelines and clinical recommendations. https://t.co/GJzR7q82si https://t.co/DOA4G1fQlV

Links:

Dr. John Cush RheumNow ( View Tweet)
Proof-of-concept, open label study of 30 #GCA pts (mean age 74 yrs) Rx w/ 12 mos of weekly tocilizumab & 8wks of prednisone. At wk 52 77% were in sustained pred-free remission & 23% relapsed at mean 16 wks (none w/ visual loss) https://t.co/Tbwhqs91Mf https://t.co/kZWkp5g87m

Links:

Dr. John Cush RheumNow ( View Tweet)
No difference in SIE/hospitalized infxn in #RA Tx w/ ABAtacept, csDMARDs or other b/tsDMARDs - from 5 data sets (2 biologic registries, NDB, 2 claims databases). IRs per 1000PYs: ABA (16-56), csDMARDs (19-46), b/tsDMARDs (18-40). No diff in OI https://t.co/WaPUNHJb76 https://t.co/uXWe7LDLpJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Difficult-to-treat (D2T) axSpA seen in 88/311 axSpA pts. D2T axSpA= failure of ≥2 b/tsDMARDs (Very D2T-axSpA: same in <2yrs). D2T had signif more periph arthritis (35 vs 21%), higher BASDAI (64 v 59) & more FM. Very D2T had more CRP, IBD, no FM https://t.co/DnxxypAEqo https://t.co/B5TxvDoYy4

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×